Full-Time

Research and Development Leadership Development Program

Posted on 3/24/2026

Deadline 4/6/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$99.7k - $104.5k/yr

+ Annual Performance Bonus + Sign-On Bonus

West Chester, PA, USA + 7 more

More locations: Bridgewater Township, NJ, USA | Irvine, CA, USA | San Carlos, CA, USA | Santa Clara, CA, USA | Bridgewater, MA, USA | Jacksonville, FL, USA | Cincinnati, OH, USA

In Person

Category
Hardware Engineering (2)
,
Required Skills
CAD
Machine Learning
Requirements
  • Currently enrolled in an Engineering Graduate Program (master’s degree) graduating between May 2025 & June 2026
  • The following engineering disciplines or specialties are preferred: Mechanical, Mechatronics, Robotics, Electrical, Computer, Systems, Software, Computer Science, Materials Science, Biomedical, Optical and Bioinformatics
  • The following concentration fields and/or skills are strongly preferred: Machine Learning, IoT, Embedded Software, Deep Machine Learning, Prototyping, Robot Design, Systems Reliability, Camera Optics, Image quality, Vision or Image Quality Assessment Firmware, and hardware integration
  • A minimum GPA of 3.3 is strongly preferred
  • You must have the ability to work closely with technical and non-technical personnel and have excellent communication skills with the ability to influence others
  • You must have the ability to demonstrate excellent critical thinking skills, intellectual curiosity, and a dedicated approach to achieving success
  • Validated leadership experience through extracurricular activities, employment, and/or internship experience is required. An R&D co-op or internship is highly preferred
  • Ability to relocate anywhere in the United States as required by the program’s rotations – a mandatory requirement
Responsibilities
  • Opportunities to participate and/or lead in rotational assignments encompassing the entire project or a substantial portion of a major project. This may include resolving advanced materials, process, inspection/testing, or procedural approaches to advance a medical device through the pipeline process into full R&D, and potentially into commercialization.
  • Support of products’ design development, manufacturing, and commercialization, leveraging technical expertise to anticipate and proactively address challenges and risks.
  • Increase the productivity of product design utilizing CAD, improve the quality of projects, improve communications through documentation, and create a database for manufacturing.
  • Engineer capabilities required to develop and deliver automated medical devices - including requisite instruments, advanced imaging, and user interface/experience.
  • Pursue several internal developmental training programs as well as externally recognized qualifications such as Process Design Excellence.
  • Opportunity to work in a fast-paced cross-functional, technologically advanced corporate environment in a program focused on developing individual engineers capable of pursuing careers across medical device businesses and high-volume manufacturers.
  • Conduct rigorous policy-focused research, synthesize evidence, and produce a range of deliverables to inform regulatory strategy, market access, and ongoing policy dialogue.
  • Help shape how we navigate global health policy, regulatory science, and biomedical innovation in a fast-moving medical device landscape.
  • Translate complex policy and scientific concepts into clear, actionable insights for cross-functional teams (R&D, Regulatory, Quality, Clinical, Marketing, and Market Access).
  • Contribute to thought leadership and public-facing communications to support policy advocacy and external engagement.
  • Collaborate on study design, evidence generation plans, and dissemination activities (conferences, webinars, publications).
  • Support project coordination and timelines for policy and regulatory initiatives, including stakeholder engagement and reporting to leadership.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • Icotyde launches with 1,500 prescriptions, Guggenheim projects $14.9 billion peak sales.
  • Atraverse Medical acquisition bolsters HOTWIRE system for atrial fibrillation ablations.
  • ETHICON 4000 Stapler gains CE Mark, reducing surgical leaks costing €5,200 per case.

What critics are saying

  • Stelara sales plummet 60% to $656 million from Amgen and Samsung biosimilars.
  • Over 90,000 talc lawsuits trigger $966 million October 2025 verdict against J&J.
  • CARVYKTI manufacturing shortfalls cap multiple myeloma sales growth in 2026.

What makes Johnson & Johnson unique

  • Diversified revenue spans Innovative Medicine, MedTech, and consumer health segments.
  • DARZALEX sales hit $4 billion in Q1 2026, exceeding forecasts by $600 million.
  • CARTO System marks 30 years, powering AI-driven CARTOSOUND SONATA for electrophysiology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Company News

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

Yahoo Finance
Apr 1st, 2026
J&J takes over NBTXR3 Phase III as Nanobiotix shifts to Curadigm, secures runway into early 2028

Nanobiotix has transferred full operational and financial responsibility for its NBTXR3 radioenhancer programme to Johnson & Johnson, with Phase III head-and-neck results expected in H1 2027 and Phase II lung cancer data anticipated in early 2027. The company is pivoting towards its Curadigm nanoprimer platform, filing four patents, starting GMP manufacturing and signing over 20 material transfer agreements with partners. Additional Curadigm data is expected before summer's end. An amended Janssen licence removing most Phase III funding obligations, combined with a royalty financing of up to $71 million, extends Nanobiotix's cash runway into early 2028. The company reported EUR 32.6 million revenue in 2025, reduced R&D spending to EUR 23.1 million, and EUR 52.8 million cash at year-end.

INACTIVE